Ivermectin Dosing for Parasite Exposure
For empirical treatment of suspected parasite exposure in adults, administer ivermectin 200 μg/kg as a single oral dose, typically combined with albendazole 400 mg. This represents the most widely endorsed regimen across current international guidelines for addressing common helminth infections 1.
Standard Dosing by Clinical Indication
Empirical Treatment (Unknown Parasite)
- Single dose: 200 μg/kg orally combined with albendazole 400 mg 1
- This targets prepatent or undetected geohelminth infections (ascariasis, hookworm, strongyloidiasis)
- Consider retreatment 1 month after resolution of symptoms to ensure adult worms are treated 1
Specific Parasitic Infections
Strongyloidiasis (intestinal):
- 200 μg/kg as a single dose for normal immunity 1, 2
- If immunocompromised: 200 μg/kg on days 1,2,15, and 16 1
- Alternative regimen: 200 μg/kg/day for 2 consecutive days (95.2% effectiveness) 3
Onchocerciasis:
- 150-200 μg/kg as a single dose 2, 4
- FDA-approved indication at this dosing 2
- Repeat dosing may be monthly, quarterly, or biannually depending on microfilarial burden 5
Scabies:
- 200 μg/kg orally, repeated in 2 weeks 6
- Take with food to increase bioavailability 6
- Second dose necessary due to limited ovicidal activity 6
Loeffler's Syndrome (larval migration):
- 200 μg/kg once daily for 3 days during prepatent period, combined with mebendazole 1
Critical Safety Considerations
Absolute Contraindications
- Exclude Loa loa infection BEFORE treating with ivermectin in anyone who has traveled to endemic regions (Central/West Africa) 1
- Risk of severe encephalopathy if microfilarial load >8,000 mf/mL 5
- First exclude co-existing onchocerciasis in patients from endemic areas 1
Age and Weight Restrictions
- Minimum weight: 15 kg for standard dosing 7, 2
- Children <15 kg: Requires specialist consultation 7
- Children 2-5 years may require 300 μg/kg to achieve equivalent adult exposure 8
- Children 6-12 years may require 250 μg/kg for equivalent exposure 8
Pregnancy and Lactation
- Classified as "human data suggest low risk" in pregnancy 6
- Probably compatible with breastfeeding; very low levels excreted in breast milk 1
Pharmacokinetic Principles
Bioavailability enhancement:
- Administer with food for 2.5-fold increase in bioavailability 2
- Peak plasma concentrations occur approximately 4 hours post-dose 2
- Half-life: 18 hours (oral), extending to 81-91 hours in some studies 2, 9
Metabolism:
- Primarily metabolized by CYP3A4 2
- Avoid concurrent use of strong CYP3A4 inhibitors/inducers
- No dose adjustment needed for renal impairment 6
- Safety of multiple doses in severe liver disease unknown 6
Common Pitfalls to Avoid
Underdosing in children: Standard 150 μg/kg may result in subtherapeutic exposure in younger children; consider 200-300 μg/kg based on age 8, 10
Single-dose assumption for all conditions: While single-dose is effective for many parasites, strongyloidiasis in immunocompromised patients and scabies require multiple doses 1, 6
Ignoring geographic exposure: Failure to screen for Loa loa before treatment can result in fatal encephalopathy 1, 5
Expecting immediate symptom resolution: Pruritus from inflammatory response can persist for days after parasites are killed; this is not treatment failure 7
Fasting administration: Always give with food to maximize absorption 6, 2
Resistance Monitoring
Emerging ivermectin resistance has been documented in veterinary medicine 11, though human resistance remains rare. In areas of repeated mass drug administration, consider:
- Monitoring treatment efficacy through follow-up stool examinations
- Alternative agents (albendazole, mebendazole) if treatment failure suspected
- Specialist consultation for refractory cases